本研究旨在调查韩国子宫内膜癌(EC)术后管理的现状。向韩国妇科肿瘤组和韩国放射肿瘤组成员进行了一次邮件调查。共收到43所机构中的38名妇科癌症外科医生(GYNs)和31名放射肿瘤学家(RO)的回复。问卷包括有关临床决策和临床病例的一般问题。使用卡方统计比较了GYN和RO的回答。根据Gynecologic Oncology Group (GOG)-249和Endometrial Carcinoma-III的结果，这两个专家团体在早期EC的临床决策方面有类似的回答。相反，在基于GOG-258结果的回答中，GYNs最常选择顺序化化疗(CTx)和放射治疗(RT)，而ROs则更喜欢在晚期采用化疗放疗联合治疗(p<0.05)。基于GOG-258，GYNs更喜欢用CTx作为浆液性或透明细胞腺癌组织的辅助治疗，而ROs则主张采用CTx和RT的联合治疗(顺序或并行)。在临床病例问题中，与ROs相比，GYNs更容易选择单独使用CTx而非CTx和RT的组合作为代表局部晚期或不良组织学的病例问题的答案(所有的p<0.05)。本研究显示GYNs和ROs在有关EC的辅助治疗，尤其是晚期或不良组织学条件下的辅助放疗方面有不同的意见。©2023. 亚洲妇科肿瘤学会，韩国妇科肿瘤学会和日本妇科肿瘤学会。

This study aimed to investigate the current status of postoperative management of uterine endometrial cancer (EC) in Korea.A mail survey was administered to members of the Korean Gynecologic Oncology Group and Korean Radiation Oncology Group. A total of 38 gynecologic cancer surgeons (GYNs) and 31 radiation oncologists (RO) in 43 institutions was responded. The questionnaire consisted of general questions for clinical decision and clinical case questions. The GYN and RO responses were compared using chi-square statistics.The 2 expert groups had similar responses for clinical decision based on the results of the Gynecologic Oncology Group (GOG)-249 and Postoperative Radiation Therapy for Endometrial Carcinoma-III trials in the early-stage EC. In contrast, the responses based on GOG-258 results differed, as GYNs most frequently opted for sequential chemotherapy (CTx) and radiotherapy (RT), while ROs preferred concurrent chemoradiotherapy in locally advanced stage (p<0.05). Based on the GOG-258, GYNs preferred CTx alone for adjuvant treatment of serous or clear cell adenocarcinoma histology, whereas ROs advocated for combined CTx and RT (sequential or concurrent). Among the clinical case questions, GYNs were more likely than ROs to choose CTx alone rather than the combination of CTx and RT (sequential or concurrent) as the answers to case questions representing patients with locally advanced stage or unfavorable histology (all p<0.05).The present study showed several different opinions of GYNs and ROs regarding adjuvant treatment for EC, particularly for adjuvant RT in advanced stage or unfavorable histology.© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.